Vistagen Therapeutics, Inc. Common Stock (VTGN) is a publicly traded Healthcare sector company. As of November 9, 2026, VTGN trades at $0.18 with a market cap of $7.27M and a P/E ratio of -0.15. VTGN moved +0.00% today. Year to date, VTGN is -75.88%; over the trailing twelve months it is -95.93%. Its 52-week range spans $0.16 to $5.14. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces VTGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vistagen provides regulatory update after productive FDA meeting on Phase 3 fasedienol development: Vistagen said the FDA provided feedback on the LSAS as the primary endpoint for a Phase 3 study of fasedienol for social anxiety disorder. The company plans to submit a revised protocol with interim assessments; the FDA recognized fasedienol’s reported safety profile and potential benefit for patients.
| Metric | Value |
|---|---|
| Price | $0.18 |
| Market Cap | $7.27M |
| P/E Ratio | -0.15 |
| EPS | $-1.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.14 |
| 52-Week Low | $0.16 |
| Volume | 141.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.50M |
| Net Income | $-67.62M |
| Gross Margin | 0.00% |
1 analysts cover VTGN: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.